These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 8210823)

  • 1. A comparison of the power of two tests for qualitative interactions.
    Piantadosi S; Gail MH
    Stat Med; 1993 Jul; 12(13):1239-48. PubMed ID: 8210823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tests against qualitative interaction: exact critical values and robust tests.
    Silvapulle MJ
    Biometrics; 2001 Dec; 57(4):1157-65. PubMed ID: 11764256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting qualitative interactions in clinical trials: an extension of range test.
    Li J; Chan IS
    J Biopharm Stat; 2006; 16(6):831-41. PubMed ID: 17146982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mixture gatekeeping procedure based on the Hommel test for clinical trial applications.
    Brechenmacher T; Xu J; Dmitrienko A; Tamhane AC
    J Biopharm Stat; 2011 Jul; 21(4):748-67. PubMed ID: 21516567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative consistency of treatment effects in multiregional clinical trials.
    Tanaka Y; Li G; Wang Y; Chen J
    J Biopharm Stat; 2012 Sep; 22(5):988-1000. PubMed ID: 22946945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing for crossover of two hazard functions using Gail and Simon's method.
    Chen YH; Liu GH
    J Biopharm Stat; 2006 May; 16(3):313-26. PubMed ID: 16724487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculations for crossover thorough QT studies: satisfaction of regulatory threshold and assay sensitivity.
    Anand SP; Murray SC; Koch GG
    J Biopharm Stat; 2010 May; 20(3):587-603. PubMed ID: 20358438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative interactions in multifactor studies.
    Russek-Cohen E; Simon RM
    Biometrics; 1993 Jun; 49(2):467-77. PubMed ID: 8369382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for the existence of a desirable dose combination.
    Hung HM; Chi GY; Lipicky RJ
    Biometrics; 1993 Mar; 49(1):85-94. PubMed ID: 8513112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new noninferiority test for independent dichotomous variables based on a shrinkage proportion estimator.
    Almendra-Arao F
    J Biopharm Stat; 2015; 25(1):157-69. PubMed ID: 24836379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis and importance of statistical power and sample size in empirical scientific research].
    Klimek KM
    Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond effect size: consideration of the minimum effect size of interest in anesthesia trials.
    Gibbs NM; Weightman WM
    Anesth Analg; 2012 Feb; 114(2):471-5. PubMed ID: 22266696
    [No Abstract]   [Full Text] [Related]  

  • 14. Wilcoxon-Mann-Whitney test: stratify or not?
    Qu Y; Zhao YD; Rahardja D
    J Biopharm Stat; 2008; 18(6):1103-11. PubMed ID: 18991110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of large Gaussian mixed models to the analysis of 24 hour ambulatory blood pressure monitoring data in clinical trials.
    Selwyn MR; Difranco DM
    Stat Med; 1993 Sep; 12(18):1665-82. PubMed ID: 8248660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a two-stage and three-stage interim-analysis procedure.
    Overall JE; Atlas RS
    Psychol Rep; 1992 Aug; 71(1):3-14. PubMed ID: 1529071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size calculations with multiplicity adjustment for longitudinal clinical trials with missing data.
    Lu K
    Stat Med; 2012 Jan; 31(1):19-28. PubMed ID: 22162151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
    Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
    Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An efficient and exact approach for detecting trends with binary endpoints.
    Shan G; Ma C; Hutson AD; Wilding GE
    Stat Med; 2012 Jan; 31(2):155-64. PubMed ID: 22162106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.